Cellebrite DI (NASDAQ:CLBT) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Cellebrite DI (NASDAQ:CLBT) announced its earnings results on Thursday. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.08, FiscalAI reports. Cellebrite DI had a return on equity of 15.58% and a net margin of 11.43%. The business had revenue of $149.02 million for the quarter, compared to analyst estimates of $145.83 million.

Here are the key takeaways from Cellebrite DI’s conference call:

• Q3 results exceeded guidance, with ARR up 20% to $528.5 million and revenue up 18% to $149 million. Growth was broad-based: EMEA rose 22%, Asia Pacific 31%, and U.S. federal ARR growth accelerated to 18%.
• Strong execution and spending discipline lifted adjusted EBITDA 42% to $53.6 million; the company also generated $52 million in quarterly free cash flow. Cellebrite raised its full-year adjusted EBITDA outlook to $163 million–$166 million while reaffirming ARR guidance of $550 million–$560 million.
• Genesis reached $2 million in ARR in its first full quarter, with early customers using it to analyze diverse evidence and accelerate investigations. Cellebrite plans to introduce an on-premise version and develop Genesis into a broader AI-native platform in 2027, though executives said it is too early to know whether future purchases will be incremental or reallocated from existing budgets.
• Corellium faced higher-than-expected churn and limited new sales, and management expects its contribution to be near the low end of its prior range. Cellebrite also said the remaining Inseyets conversions are likely to deliver a smaller uplift and fewer expansions than in prior years.
• Management cited a shift toward cloud and AI subscriptions, which are recognized ratably, as a factor in revenue timing and forecast uncertainty; it has greater confidence in the lower end of its ARR outlook. The company expects U.S. redomiciliation, subject to approvals, to reduce customer sales friction and is targeting completion in the first half of 2027.

Cellebrite DI Price Performance

NASDAQ:CLBT traded down $1.68 during mid-day trading on Thursday, reaching $11.02. The stock had a trading volume of 4,473,304 shares, compared to its average volume of 2,257,812. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of 50.08, a price-to-earnings-growth ratio of 1.94 and a beta of 1.06. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98. The stock’s 50 day simple moving average is $11.62 and its two-hundred day simple moving average is $13.27.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, insider Thomas Hogan sold 25,299 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total transaction of $285,625.71. Following the sale, the insider owned 765,249 shares in the company, valued at $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO David Barter sold 12,134 shares of the stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $11.21, for a total value of $136,022.14. Following the transaction, the chief financial officer directly owned 322,085 shares in the company, valued at approximately $3,610,572.85. This represents a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 56,516 shares of company stock valued at $636,660 in the last three months. Corporate insiders own 5.70% of the company’s stock.

Wall Street Analysts Forecast Growth

CLBT has been the subject of a number of analyst reports. DA Davidson reissued a “buy” rating and issued a $15.00 price target on shares of Cellebrite DI in a report on Tuesday, September 15th. Needham & Company LLC dropped their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a report on Friday, August 14th. Weiss Ratings lowered Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. reduced their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Finally, Lake Street Capital decreased their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.70.

About Cellebrite DI

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.